Vascular disrupting agents

M J Pilat1, P M Lorusso

  • 1Department of Internal Medicine, Division of Hematology/Oncology, Karmanos Cancer Institute, Detroit, Michigan 48201, USA.

Insights

Vascular disrupting agents (VDAs) target established tumor blood vessels, causing necrosis. VDAs show promise against advanced cancers, especially when combined with treatments targeting remaining tumor cells.

Area of Science:

  • Oncology
  • Vascular Biology
  • Drug Development

Background:

  • Solid tumor growth and metastasis depend on a functional vascular supply.
  • Tumor angiogenesis, the formation of new blood vessels, is crucial for tumor progression.
  • Targeting tumor vasculature is a key strategy in cancer therapy.

Purpose of the Study:

  • To review the role of vascular disrupting agents (VDAs) in cancer treatment.
  • To compare VDAs with antiangiogenic agents.
  • To explore the potential of VDAs in combination therapies.

Main Methods:

  • Review of existing research on VDAs and antiangiogenic agents.
  • Analysis of VDA mechanisms, efficacy, and limitations.
  • Discussion of VDA classification (ligand-bound and small molecule).

Main Results:

  • VDAs target established tumor vasculature, leading to ischemia and necrosis.
  • VDAs demonstrate more immediate effects than antiangiogenic agents and may be effective in advanced disease.
  • Both VDA types induce tumor core necrosis but leave a viable rim of tumor cells.

Conclusions:

  • VDAs are a distinct class of antitumor agents targeting existing tumor vasculature.
  • VDAs show potential efficacy, particularly in advanced or bulky tumors.
  • Combination therapy, pairing VDAs with agents targeting the peripheral tumor rim, is a promising strategy.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Vascular Spasm01:16

Vascular Spasm

The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last for...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Varicose Veins II: Diagnostic Studies and Interprofessional Care01:26

Varicose Veins II: Diagnostic Studies and Interprofessional Care

Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...